Podarcis wall lizards are endemic to the Mediterranean Basin the place they symbolize the predominant reptile group. Despite being extensively used as mannequin organisms in evolutionary and ecological research their phylogeny and historic biogeography are nonetheless incompletely resolved. Moreover, molecular clock calibrations utilized in wall lizard phylogeography are primarily based on the idea of vicariant speciation triggered by the abrupt Mediterranean Sea stage rise on the finish of the Messinian salinity disaster (MSC). However, the validity of this biogeographic calibration stays untested.
In this research we inferred a sturdy time tree primarily based on multilocus information and fossil calibrations utilizing each gene concatenation and species-tree approaches and together with models with gene-flow. We discovered 5 deeply divergent, geographically coherent, and well-supported clades comprising species from i) Iberian Peninsula and North Africa; ii) Western Mediterranean islands, iii) Sicilian and Maltese islands; and iv-v) Balkan area and Aegean islands. The mitochondrial tree exhibits some inconsistencies with the species tree that warrant future investigation. Diversification of foremost clades is estimated in a brief time body in the course of the Middle Miocene and may need been related to a interval of international local weather cooling with the institution of a marked climatic zonation in Europe.
Cladogenetic occasions inside the principle clades are scattered all through the time tree, from the Late Miocene to the Early Pleistocene, suggesting that speciation occasions in wall lizards replicate a fancy interaction between areaal topography, local weather and geological historical past reasonably than a shared main climatic or paleogeographic occasion. Our absolute time estimates, in addition to a relative courting strategy, show that the idea of a causal hyperlink between sea-level rise on the finish of the MSC and the diversification of many island endemics isn’t justified. This research reinforces the notion that a number of dispersal and vicariant occasions, at totally different time frames, are required to elucidate present allopatric distributions and to account for the historic meeting of Mediterranean biota, and cautions in opposition to the use of biogeographic calibrations primarily based on the idea of vicariance.
The 30 October 2020 Aegean Sea Tsunami: Post-Event Field Survey Along Turkish Coast
On 30 October 2020, a powerful normal-faulting earthquake struck Samos Island in Greece and İzmir Province in Turkey, each within the japanese Aegean Sea. The earthquake generated a tsunami that hit the coasts of Samos Island, Greece and İzmir, Turkey. National groups carried out two post-tsunami discipline surveys on 31 October to 1 November 2020, and 4-6 November 2020, alongside the Turkish shoreline; whereas the previous was a fast survey on the times following the tsunami, the latter concerned extra detailed measurement and investigation specializing in a ~ 110-km-long shoreline extending from Alaçatı (Çeşme District of İzmir) to Gümüldür (Menderes District of İzmir). The survey groups measured runup and tsunami heights, circulate depths, and inundation distances at greater than 120 factors at eight totally different localities.
The largest tsunami runup among the many surveyed areas was measured as 3.eight m in Akarca at a distance of 91 m from the shoreline. The most tsunami peak of 2.Three m (with a circulate depth of 1.Four m) was noticed at Kaleiçi area in Sığacık, the place probably the most extreme tsunami harm was noticed. There, the utmost runup peak was measured as 1.9 m on the northeastern facet of the bay. The survey workforce additionally investigated tsunami harm to coastal constructions, noticing a gradual lower within the affect from Gümüldür to additional southeast.
The findings of this discipline survey present insights into the coastal affect of native tsunamis within the Aegean Sea. Elucidating the genetic variation and construction of Lemnos and Lesvos sheep is vital for sustaining native genetic variety, ecosystem integrity and resilience of native meals manufacturing of the 2 North Aegean islands. In the current research, we explored genetic variety and differentiation in addition to inhabitants construction of the Lemnos and Lesvos sheep. Furthermore, we sought to determine a small panel of markers with the very best discriminatory energy to assign animals throughout islands.
Greece and Turkey Shaken by African tectonic retreat
Earthquakes are a consequence of the motions of the planet’s tectonic plates, but predicting when and the place they could happen, and learn how to put together stay some of the shortcomings of utilizing scientific data to guard human life. A devastating Mw 7.zero earthquake on October 30, 2020, offshore Samos Island, Greece was a consequence of the Aegean and Anatolian higher crust being pulled aside by north-south extensional stresses ensuing from slab rollback, the place the African plate is subducting northwards beneath Eurasia, whereas the slab is sinking by gravitational forces, inflicting it to retreat southwards.
Since the retreating African slab is coupled with the overriding plate, it tears the higher plate aside because it retreats, breaking it into quite a few small plates with frequent earthquakes alongside their boundaries. Historical earthquake swarms and deformation of the higher plate within the Aegean have been related to huge volcanism and cataclysmic devastation, such because the Mw 7.7 Amorgos earthquake in July 1956 between the islands of Naxos and Santorini (Thera).
Recombinant Varicella-zoster virus Envelope glycoprotein L (gL) |
|||
| RPC27678-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein L (gL) |
|||
| RPC27678-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein L (gL) |
|||
| RPC27678-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC27662-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC27662-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC27662-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC28392-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC28392-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Varicella-zoster virus Envelope glycoprotein H (gH) ,partial |
|||
| RPC28392-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Epstein-Barr virus Envelope glycoprotein GP350 (BLLF1) ,partial |
|||
| RPC20293-100ug | Biomatik Corporation | 100ug | 721.6 EUR |
Recombinant Epstein-Barr virus Envelope glycoprotein GP350 (BLLF1) ,partial |
|||
| RPC20293-1mg | Biomatik Corporation | 1mg | 2884.7 EUR |
Recombinant Epstein-Barr virus Envelope glycoprotein GP350 (BLLF1) ,partial |
|||
| RPC20293-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant EBOV Envelope Glycoprotein (aa 33-637) |
|||
| VAng-0669Lsx-100g | Creative Biolabs | 100 µg | 1017.6 EUR |
|
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Recombinant EBOV Envelope Glycoprotein (aa 33-637) |
|||
| VAng-0669Lsx-1mg | Creative Biolabs | 1 mg | 5998.8 EUR |
|
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Borna disease virus Envelope glycoprotein p57 (G) |
|||
| 1-CSB-CF345219BIN | Cusabio |
|
|
|
Description: Recombinant Borna disease virus Envelope glycoprotein p57(G),partial expressed in in vitro E.coli expression system |
|||
Epstein-Barr virus Envelope glycoprotein B (gB) |
|||
| 1-CSB-EP355975EFA | Cusabio |
|
|
|
Description: Recombinant Epstein-Barr virus Envelope glycoprotein B(gB),partial expressed in E.coli |
|||
Epstein-Barr virus Envelope glycoprotein L (gL) |
|||
| 1-CSB-EP355982EFA | Cusabio |
|
|
|
Description: Recombinant Epstein-Barr virus Envelope glycoprotein L(gL) expressed in E.coli |
|||
Epstein-Barr virus Envelope glycoprotein H (gH) |
|||
| 1-CSB-EP365883EFA | Cusabio |
|
|
|
Description: Recombinant Epstein-Barr virus Envelope glycoprotein H(gH),partial expressed in E.coli |
|||
Recombinant (E.coli) Bovine Viral Diarrhea Virus 1 Envelope glycoprotein 2 (BVDV1-E2, His-tag) purified |
|||
| BVDE15-R-10 | Alpha Diagnostics | 10 ug | 416.4 EUR |
Varicella-zoster virus Envelope glycoprotein E (gE) |
|||
| 1-CSB-CF362630VAP | Cusabio |
|
|
|
Description: Recombinant Varicella-zoster virus Envelope glycoprotein E(gE) expressed in in vitro E.coli expression system |
|||
Epstein-Barr virus Envelope glycoprotein GP350 (BLLF1) |
|||
| 1-CSB-EP360986EFA | Cusabio |
|
|
|
Description: Recombinant Epstein-Barr virus Envelope glycoprotein GP350(BLLF1),partial expressed in E.coli |
|||
Recombinant Feline Leukemia Virus p27 Antigen |
|||
| E41H082 | EnoGene | 100ug | 395 EUR |
Human CellExp? Recombinant EBOV Envelope Glycoprotein 1 |
|||
| P1060-10 | Biovision | each | 170.4 EUR |
Human CellExp? Recombinant EBOV Envelope Glycoprotein 1 |
|||
| P1060-50 | Biovision | each | 483.6 EUR |
Recombinant Human herpesvirus 2 Envelope glycoprotein E (gE) |
|||
| RPC27442-100ug | Biomatik Corporation | 100ug | 3705.6 EUR |
Recombinant Human herpesvirus 2 Envelope glycoprotein E (gE) |
|||
| RPC27442-20ug | Biomatik Corporation | 20ug | 2377 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein G (gG) |
|||
| RPC27446-100ug | Biomatik Corporation | 100ug | 3216.5 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein G (gG) |
|||
| RPC27446-20ug | Biomatik Corporation | 20ug | 1992.8 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein L (gL) |
|||
| RPC23347-100ug | Biomatik Corporation | 100ug | 721.6 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein L (gL) |
|||
| RPC23347-1mg | Biomatik Corporation | 1mg | 2884.7 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein L (gL) |
|||
| RPC23347-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-1mg |
|||
| QP7033-ec-1mg | EnQuireBio | 1mg | 1958.4 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-1mg |
|||
| QP7363-ec-1mg | EnQuireBio | 1mg | 1958.4 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-10ug |
|||
| QP7033-ec-10ug | EnQuireBio | 10ug | 240 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-50ug |
|||
| QP7033-ec-50ug | EnQuireBio | 50ug | 315.6 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-10ug |
|||
| QP7363-ec-10ug | EnQuireBio | 10ug | 240 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-50ug |
|||
| QP7363-ec-50ug | EnQuireBio | 50ug | 315.6 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-100ug |
|||
| QP7033-ec-100ug | EnQuireBio | 100ug | 489.6 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-200ug |
|||
| QP7033-ec-200ug | EnQuireBio | 200ug | 760.8 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-500ug |
|||
| QP7033-ec-500ug | EnQuireBio | 500ug | 1272 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-100ug |
|||
| QP7363-ec-100ug | EnQuireBio | 100ug | 489.6 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-200ug |
|||
| QP7363-ec-200ug | EnQuireBio | 200ug | 760.8 EUR |
Recombinant Human Envelope glycoprotein 1, His-SUMO, E.coli-500ug |
|||
| QP7363-ec-500ug | EnQuireBio | 500ug | 1272 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-1mg |
|||
| QP7456-ye-1mg | EnQuireBio | 1mg | 3296.4 EUR |
Recombinant Human herpesvirus 2 Envelope glycoprotein B (gB) ,partial |
|||
| RPC20534-100ug | Biomatik Corporation | 100ug | 721.6 EUR |
Recombinant Human herpesvirus 2 Envelope glycoprotein B (gB) ,partial |
|||
| RPC20534-1mg | Biomatik Corporation | 1mg | 2884.7 EUR |
Recombinant Human herpesvirus 2 Envelope glycoprotein B (gB) ,partial |
|||
| RPC20534-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein D (gD) ,partial |
|||
| RPC27321-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein D (gD) ,partial |
|||
| RPC27321-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein D (gD) ,partial |
|||
| RPC27321-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein C (gC) ,partial |
|||
| RPC27595-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein C (gC) ,partial |
|||
| RPC27595-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Human herpesvirus 1 Envelope glycoprotein C (gC) ,partial |
|||
| RPC27595-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Human herpesvirus 6A Envelope glycoprotein B (gB) ,partial |
|||
| RPC27644-100ug | Biomatik Corporation | 100ug | 801.9 EUR |
Recombinant Human herpesvirus 6A Envelope glycoprotein B (gB) ,partial |
|||
| RPC27644-1mg | Biomatik Corporation | 1mg | 2885.2 EUR |
Recombinant Human herpesvirus 6A Envelope glycoprotein B (gB) ,partial |
|||
| RPC27644-20ug | Biomatik Corporation | 20ug | 448.1 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-100ug |
|||
| QP7456-ye-100ug | EnQuireBio | 100ug | 979.2 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-10ug |
|||
| QP7456-ye-10ug | EnQuireBio | 10ug | 445.2 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-200ug |
|||
| QP7456-ye-200ug | EnQuireBio | 200ug | 1555.2 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-500ug |
|||
| QP7456-ye-500ug | EnQuireBio | 500ug | 2164.8 EUR |
Recombinant Cytomegalovirus Envelope glycoprotein 1, His, Yeast-50ug |
|||
| QP7456-ye-50ug | EnQuireBio | 50ug | 598.8 EUR |
Recombinant Rhesus cytomegalovirus Envelope glycoprotein B (gB) ,partial |
|||
| RPC22360-100ug | Biomatik Corporation | 100ug | 572 EUR |
Recombinant Rhesus cytomegalovirus Envelope glycoprotein B (gB) ,partial |
|||
| RPC22360-1mg | Biomatik Corporation | 1mg | 2884.7 EUR |
Recombinant Rhesus cytomegalovirus Envelope glycoprotein B (gB) ,partial |
|||
| RPC22360-20ug | Biomatik Corporation | 20ug | 353.4 EUR |
Recombinant Human cytomegalovirus Envelope glycoprotein H (gH) ,partial |
|||
| RPC22405-100ug | Biomatik Corporation | 100ug | 460.9 EUR |
Recombinant Human cytomegalovirus Envelope glycoprotein H (gH) ,partial |
|||
| RPC22405-1mg | Biomatik Corporation | 1mg | 2237.8 EUR |
Recombinant Human cytomegalovirus Envelope glycoprotein H (gH) ,partial |
|||
| RPC22405-20ug | Biomatik Corporation | 20ug | 258.7 EUR |
Epstein-Barr virus Envelope Glycoprotein B (gB), His Tag (MALS verified) |
|||
| GLB-E52H3 | ACROBIOSYSTEMS | 100ug | 406.6 EUR |
|
Description: Epstein-Barr virus Envelope Glycoprotein B (gB), His Tag (GLB-E52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 23 - Gly 685 (Accession # P03188 (W112H, Y113R, R428G, R429S, R430G, R431S, R432G, W193R, L194V, I195E, W196A)). |
|||
Human CellExp? Recombinant Ebolavirus BDBV Envelope Glycoprotein 1 (GP1) |
|||
| P1061-10 | Biovision | each | 170.4 EUR |
Human CellExp? Recombinant Ebolavirus BDBV Envelope Glycoprotein 1 (GP1) |
|||
| P1061-50 | Biovision | each | 483.6 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-10ug |
|||
| QP7278-ec-10ug | EnQuireBio | 10ug | 391.2 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-1mg |
|||
| QP7278-ec-1mg | EnQuireBio | 1mg | 2763.6 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-50ug |
|||
| QP7278-ec-50ug | EnQuireBio | 50ug | 522 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-10ug |
|||
| QP7411-ec-10ug | EnQuireBio | 10ug | 391.2 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-1mg |
|||
| QP7411-ec-1mg | EnQuireBio | 1mg | 2763.6 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-50ug |
|||
| QP7411-ec-50ug | EnQuireBio | 50ug | 522 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-100ug |
|||
| QP7278-ec-100ug | EnQuireBio | 100ug | 848.4 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-200ug |
|||
| QP7278-ec-200ug | EnQuireBio | 200ug | 1338 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-500ug |
|||
| QP7278-ec-500ug | EnQuireBio | 500ug | 1816.8 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-100ug |
|||
| QP7411-ec-100ug | EnQuireBio | 100ug | 848.4 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-200ug |
|||
| QP7411-ec-200ug | EnQuireBio | 200ug | 1338 EUR |
Recombinant Epstein-Barr Envelope glycoprotein 1, His-SUMO, E.coli-500ug |
|||
| QP7411-ec-500ug | EnQuireBio | 500ug | 1816.8 EUR |
Recombinant 1 Envelope glycoprotein 2 (1 E2) Protein control for western blot |
|||
| BVDE11-C | Alpha Diagnostics | 100 ul | 343.2 EUR |
Human Immunodeficiency Virus 1 Envelope Glycoprotein gp120 (HIV1 gp120) Antibody |
|||
| abx412175-1mg | Abbexa | 1 mg | 610.8 EUR |
Human Immunodeficiency Virus 1 Envelope Glycoprotein gp120 (HIV1 gp120) Antibody |
|||
| abx411417-1ml | Abbexa | 1 ml | 610.8 EUR |
Mouse Anti Epstein-Barr Virus Envelope Glycoprotein Complex Monoclonal Antibody |
|||
| DMABT-51230ME | Creative Diagnostics | 0.1 mg | 1070.4 EUR |
Feline leukemia virus |
|||
| PCR-V176-PCRV17648R | Bioingentech | PCR-V176-48R | 485 EUR |
Feline leukemia virus |
|||
| PCR-V176-PCRV17696R | Bioingentech | PCR-V176-96R | 685 EUR |
Feline leukemia virus |
|||
| Oneq-V176-OneqV176100R | Bioingentech | Oneq-V176-100R | 1028 EUR |
Feline leukemia virus |
|||
| Oneq-V176-OneqV176150R | Bioingentech | Oneq-V176-150R | 1438 EUR |
Feline leukemia virus |
|||
| Oneq-V176-OneqV17650R | Bioingentech | Oneq-V176-50R | 728 EUR |
Human Immunodeficiency Virus 1 Envelope Glycoprotein gp120 (HIV1 gp120) Antibody (HRP) |
|||
| abx411419-1ml | Abbexa | 1 ml | 760.8 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-10ug |
|||
| QP7351-ec-10ug | EnQuireBio | 10ug | 391.2 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-1mg |
|||
| QP7351-ec-1mg | EnQuireBio | 1mg | 2763.6 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-50ug |
|||
| QP7351-ec-50ug | EnQuireBio | 50ug | 522 EUR |
Human Immunodeficiency Virus 1 Envelope Glycoprotein gp120 (HIV1 gp120) Antibody (Biotin) |
|||
| abx411418-1ml | Abbexa | 1 ml | 710.4 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-100ug |
|||
| QP7351-ec-100ug | EnQuireBio | 100ug | 848.4 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-200ug |
|||
| QP7351-ec-200ug | EnQuireBio | 200ug | 1338 EUR |
Recombinant Epstein-Barr Envelope glycoprotein GP350 Protein, His-SUMO, E.coli-500ug |
|||
| QP7351-ec-500ug | EnQuireBio | 500ug | 1816.8 EUR |
Recombinant (E.coli) Mayaro virus (MAYV) E1 Envelop Glycoprotein (Brazil strain, >95% Pure, His-tag) |
|||
| MAYV11-R-100 | Alpha Diagnostics | 100 ug | 416.4 EUR |
Human immunodeficiency virus type 1 group M subtype B Envelope glycoprotein gp160 (env) |
|||
| 1-CSB-EP361302HKP | Cusabio |
|
|
|
Description: Recombinant Human immunodeficiency virus type 1 group M subtype B Envelope glycoprotein gp160(env),partial expressed in E.coli |
|||
Rabbit Anti-Bovine Viral Diarrhea Virus 2 Envelope glycoprotein 2 (BVDV2 E2) protein antiserum |
|||
| BVDE21-S | Alpha Diagnostics | 100 ul | 548.4 EUR |
HHV-2 Envelope Glycoprotein G (552-574) |
|||
| H-7998.0500 | Bachem | 0.5mg | 297.6 EUR |
|
Description: Sum Formula: C103H146N28O38; CAS# [2022956-63-2] net |
|||
HHV-2 Envelope Glycoprotein G (552-574) |
|||
| H-7998.1000 | Bachem | 1.0mg | 501.6 EUR |
|
Description: Sum Formula: C103H146N28O38; CAS# [2022956-63-2] net |
|||
Recombinant (E. coli) Mayaro virus (MAYV) E2 Envelop Glycoprotein (Brazil strain, aa: 325-690, >95% Pure, His-tag) |
|||
| MAYV21-R-100 | Alpha Diagnostics | 100 ug | 416.4 EUR |
Envelope glycoprotein B (GB) Antibody |
|||
| 20-abx317791 | Abbexa |
|
|
Feline Leukemia virus antibody |
|||
| 10C-CR1297M1 | Fitzgerald | 100 ug | 296.4 EUR |
|
Description: Mouse monoclonal Feline Leukemia virus antibody |
|||
Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (MALS verified) |
|||
| GLE-V52H3 | ACROBIOSYSTEMS | 100ug | 246.1 EUR |
|
Description: Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (GLE-V52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 31 - Ala 546 (Accession # Q9J3M8-1). |
|||
Feline leukemia virus PCR kit |
|||
| PCR-V176-48R | Bioingentech | 50T | 987.6 EUR |
Feline leukemia virus PCR kit |
|||
| PCR-V176-96R | Bioingentech | 100T | 1335.6 EUR |
Zaire ebolavirus Envelope glycoprotein (GP) |
|||
| 1-CSB-YP310843ZAA | Cusabio |
|
|
|
Description: Recombinant Zaire ebolavirus Envelope glycoprotein(GP),partial expressed in Yeast |
|||
Sudan ebolavirus Envelope glycoprotein (GP) |
|||
| 1-CSB-YP742487SRE | Cusabio |
|
|
|
Description: Recombinant Sudan ebolavirus Envelope glycoprotein(GP),partial expressed in Yeast |
|||
Zaire ebolavirus Envelope glycoprotein (GP) |
|||
| 1-CSB-EP311249ZAT | Cusabio |
|
|
|
Description: Recombinant Zaire ebolavirus Envelope glycoprotein(GP),partial expressed in E.coli |
|||
Sudan ebolavirus Envelope glycoprotein (GP) |
|||
| 1-CSB-MP742487SRE | Cusabio |
|
|
|
Description: Recombinant Sudan ebolavirus Envelope glycoprotein (GP) ,partial expressed in Mammalian cell |
|||
Envelope glycoprotein B (GB) Antibody (HRP) |
|||
| 20-abx317792 | Abbexa |
|
|
Envelope Glycoprotein GP350 (BLLF1) Antibody |
|||
| 20-abx319925 | Abbexa |
|
|
Envelope glycoprotein B (GB) Antibody (FITC) |
|||
| 20-abx317793 | Abbexa |
|
|
Feline Leukemia Virus p27 protein |
|||
| 30-1928 | Fitzgerald | 100 ug | 548.4 EUR |
|
Description: Recombinant FeLV p27 protein with his tag |
|||
Envelope glycoprotein B (GB) Antibody (Biotin) |
|||
| 20-abx317794 | Abbexa |
|
|
Feline Leukemia Virus p27 antibody |
|||
| 10-1520 | Fitzgerald | 100 ug | 404.4 EUR |
|
Description: Mouse monoclonal Feline Leukemia Virus p27 antibody |
|||
Feline Leukemia virus p27 antibody |
|||
| 10-F05A | Fitzgerald | 250 ug | 369.6 EUR |
|
Description: Mouse monoclonal Feline Leukemia virus antibody |
|||
Feline Leukemia Virus p27 antibody |
|||
| 10-F05C | Fitzgerald | 250 ug | 260.4 EUR |
|
Description: Mouse monoclonal Feline Leukemia Virus p27 antibody |
|||
Feline Leukemia Virus p27 antibody |
|||
| 20-FG32 | Fitzgerald | 1 mg | 153.6 EUR |
|
Description: Goat polyclonal Feline Leukemia Virus p27 antibody |
|||
Herpesvirus Envelope glycoprotein D Antibody |
|||
| 20-abx109865 | Abbexa |
|
|
Feline Leukemia Virus gp70 antibody |
|||
| 10-F07A | Fitzgerald | 250 ug | 392.4 EUR |
|
Description: Mouse monoclonal Feline Leukemia Virus gp70 antibody |
|||
Feline Leukemia Virus gp70 antibody |
|||
| 10-F07B | Fitzgerald | 250 ug | 392.4 EUR |
|
Description: Mouse monoclonal Feline Leukemia Virus gp70 antibody |
|||
Feline leukemia virus RT PCR kit |
|||
| RTq-V176-100R | Bioingentech | 100T | 1573.2 EUR |
Feline leukemia virus RT PCR kit |
|||
| RTq-V176-150R | Bioingentech | 150T | 2144.4 EUR |
Feline leukemia virus RT PCR kit |
|||
| RTq-V176-50R | Bioingentech | 50T | 1155.6 EUR |
FITC-eAhx-HHV-2 Envelope Glycoprotein G (561-578) |
|||
| H-8002.0500 | Bachem | 0.5mg | 312 EUR |
|
Description: Sum Formula: C104H128N20O44S; CAS# [2022956-64-3] |
|||
FITC-eAhx-HHV-2 Envelope Glycoprotein G (561-578) |
|||
| H-8002.1000 | Bachem | 1.0mg | 507.6 EUR |
|
Description: Sum Formula: C104H128N20O44S; CAS# [2022956-64-3] |
|||
Cytomegalovirus Envelope Glycoprotein H Antibody |
|||
| 20-abx109273 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein L Antibody |
|||
| 20-abx109402 | Abbexa |
|
|
Herpesvirus 1 Envelope glycoprotein G Antibody |
|||
| 20-abx109864 | Abbexa |
|
|
Human herpesvirus 1 Envelope glycoprotein G (gG) |
|||
| 1-CSB-EP361844HWY | Cusabio |
|
|
|
Description: Recombinant Human herpesvirus 1 Envelope glycoprotein G(gG),partial expressed in E.coli |
|||
Human herpesvirus 2 Envelope glycoprotein B (gB) |
|||
| 1-CSB-EP362479HJX | Cusabio |
|
|
|
Description: Recombinant Human herpesvirus 2 Envelope glycoprotein B (gB),partial expressed in E.coli |
|||
Human herpesvirus 1 Envelope glycoprotein L (gL) |
|||
| 1-CSB-EP836165HSP | Cusabio |
|
|
|
Description: Recombinant Human herpesvirus 1 Envelope glycoprotein L(gL) expressed in E.coli |
|||
Human herpesvirus 1 Envelope glycoprotein B (gB) |
|||
| 1-CSB-EP318023HWY | Cusabio |
|
|
|
Description: Recombinant Human herpesvirus 1 Envelope glycoprotein B(gB),partial expressed in E.coli |
|||
Herpesvirus Envelope glycoprotein D Antibody (HRP) |
|||
| 20-abx108347 | Abbexa |
|
|
Human cytomegalovirus Envelope glycoprotein L (gL) |
|||
| 1-CSB-EP515269HWW | Cusabio |
|
|
|
Description: Recombinant Human cytomegalovirus Envelope glycoprotein L(gL) expressed in E.coli |
|||
Human cytomegalovirus Envelope glycoprotein H (gH) |
|||
| 1-CSB-YP319015HWV | Cusabio |
|
|
|
Description: Recombinant Human cytomegalovirus Envelope glycoprotein H(gH),partial expressed in Yeast |
|||
Human cytomegalovirus Envelope glycoprotein L (gL) |
|||
| 1-CSB-YP515269HWW | Cusabio |
|
|
|
Description: Recombinant Human cytomegalovirus Envelope glycoprotein L(gL) expressed in Yeast |
|||
Human cytomegalovirus Envelope glycoprotein H (gH) |
|||
| 1-CSB-EP319015HWV | Cusabio |
|
|
|
Description: Recombinant Human cytomegalovirus Envelope glycoprotein H(gH),partial expressed in E.coli |
|||
Herpesvirus Envelope glycoprotein D Antibody (FITC) |
|||
| 20-abx106925 | Abbexa |
|
|
Rhesus cytomegalovirus Envelope glycoprotein B (gB) |
|||
| 1-CSB-EP309330RKC | Cusabio |
|
|
|
Description: Recombinant Rhesus cytomegalovirus Envelope glycoprotein B(gB),partial expressed in E.coli |
|||
Feline Leukemia Virus p27 antibody (HRP) |
|||
| 60-5006 | Fitzgerald | 1 ml | 490.8 EUR |
|
Description: Goat polyclonal Feline Leukemia Virus p27 antibody (HRP) |
|||
Lake Victoria marburgvirus Envelope glycoprotein (GP) |
|||
| 1-CSB-BP330440LBR | Cusabio |
|
|
|
Description: Recombinant Lake Victoria marburgvirus Envelope glycoprotein(GP),partial expressed in Baculovirus |
|||
Lake Victoria marburgvirus Envelope glycoprotein (GP) |
|||
| 1-CSB-EP330440LBR | Cusabio |
|
|
|
Description: Recombinant Lake Victoria marburgvirus Envelope glycoprotein(GP),partial expressed in E.coli |
|||
Herpesvirus Envelope glycoprotein D Antibody (Biotin) |
|||
| 20-abx105508 | Abbexa |
|
|
Herpesvirus 1 Envelope glycoprotein G Antibody (HRP) |
|||
| 20-abx108346 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein H Antibody (HRP) |
|||
| 20-abx108160 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein L Antibody (HRP) |
|||
| 20-abx109036 | Abbexa |
|
|
Feline Leukemia Virus p27 antibody (biotin) |
|||
| 60-5007 | Fitzgerald | 1 ml | 453.6 EUR |
|
Description: Goat polyclonal Feline Leukemia Virus p27 antibody (biotin) |
|||
Herpesvirus 1 Envelope glycoprotein G Antibody (FITC) |
|||
| 20-abx106924 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein H Antibody (FITC) |
|||
| 20-abx106741 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein L Antibody (FITC) |
|||
| 20-abx107619 | Abbexa |
|
|
Feline leukemia virus One-Step PCR kit |
|||
| Oneq-V176-100R | Bioingentech | 100T | 1932 EUR |
Feline leukemia virus One-Step PCR kit |
|||
| Oneq-V176-150R | Bioingentech | 150T | 2646 EUR |
Feline leukemia virus One-Step PCR kit |
|||
| Oneq-V176-50R | Bioingentech | 50T | 1410 EUR |
Herpesvirus 1 Envelope glycoprotein G Antibody (Biotin) |
|||
| 20-abx105507 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein H Antibody (Biotin) |
|||
| 20-abx105322 | Abbexa |
|
|
Cytomegalovirus Envelope Glycoprotein L Antibody (Biotin) |
|||
| 20-abx106203 | Abbexa |
|
|
Feline Leukemia Virus(FeLV) Antigen Test Card |
|||
| C11161 | Ring Biotechnology Co | 15T | Ask for price |
Even extra notable was the eruption of Santorini 3650 years in the past, which contributed to the autumn of the Minoan civilization. The Samos earthquake highlights the lengthy historic lack of appreciation of hyperlinks between deep tectonic processes and higher crustal deformation and geological hazards, and is a harbinger of future earthquakes and volcanic eruptions, establishing a foundation for research to institute higher safety of infrastructure and higher plate cultures within the area.